0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 21, 2025 07:39 ET (11:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。